ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

migalastat

Also written as “Lucerastat”, “migalastat HCl” and “migalastat HCl 150 mg”.

Its studies are mostly in Fabry Disease, led by 2 companies.

Drug pageMigalastat: every studyAll 24 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Jun 19, 200924 company-led studies, 3 open or runningNext primary completion: Dec 31, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
BioMarin Pharmaceutical172 open or runningphase 3since Jun 19, 2009Sep 13, 2005Dec 31, 2026phase 3 · NCT04020055
Idorsia Pharmaceuticalsits history only71 open or runningphase 3since Jan 16, 2018Oct 24, 2016Feb 13, 2029phase 3 · NCT07778667

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of BioMarin Pharmaceutical only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 3 studies since Sep 13, 2005.

  1. Mar 17, 2006Phase 2 study in Fabry DiseaseNCT00304512 · 9 enrolled · United States, Australia, Brazil and more
  2. Sep 5, 2007Phase 2 study in Fabry DiseaseNCT00526071 · 23 enrolled · United States, Australia, Brazil and more
  3. Jun 19, 2009Phase 3 study in Fabry DiseaseNCT00925301 · 67 enrolled · United States, Argentina, Australia and more
  4. Sep 7, 2010Phase 2 study in Fabry DiseaseNCT01196871 · 20 enrolled · United States, Australia, Belgium and more
  5. Oct 6, 2010Phase 3 study in Fabry DiseaseNCT01218659 · 68 enrolled · United States, Australia, Austria and more
  6. Oct 20, 2011Phase 1 study in Fabry DiseaseNCT01489995 · 20 enrolled · United States
  7. Oct 20, 2011Phase 3 study in Fabry DiseaseNCT01458119 · 85 enrolled · United States, Argentina, Australia and more
  8. Nov 10, 2011Phase 1 study in Fabry DiseaseNCT01853852 · 14 enrolled · Australia
  9. Mar 6, 2014Phase 1 study in Fabry DiseaseNCT02082327 · 31 enrolled · Netherlands
  10. Jul 17, 2014Phase 3 study in Fabry DiseaseNCT02194985 · 84 enrolled · United States, Argentina, Australia and more
  11. Apr 9, 2018Phase 3 study in Fabry DiseaseNCT03500094 · 22 enrolled · United States, United Kingdom
  12. Jun 24, 2019Phase 3 study in Fabry DiseaseNCT04020055 · 14 enrolled · United States, Australia, Japan and more
  13. Jul 30, 2019Phase 3 study in Fabry DiseaseNCT04049760 · 16 enrolled · United States, United Kingdom
  14. Mar 13, 2025Phase 3 study in Fabry DiseaseNCT06904261 · 8 planned · United States, Belgium, Germany and more

Ahead

  1. Dec 31, 2026Primary completion: phase 3 study in Fabry DiseaseNCT04020055
  2. Dec 2027Primary completion: phase 3 study in Fabry DiseaseNCT06904261

TargetBeta

GLA →read by rule
“Alpha-galactosidase A stabiliser; Alpha-galactosidase A stabiliser”ChEMBL 37, by rule

Studies

All 17 BioMarin Pharmaceutical leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06904261Fabry Disease · United States, Belgium, Germany and more3RecruitingDec 20278
NCT04049760Fabry Disease · United States, United Kingdom3CompletedNov 29, 202416
NCT04020055Fabry Disease · United States, Australia, Japan and more3Active, not recruitingDec 31, 202614
NCT03500094Fabry Disease · United States, United Kingdom3CompletedFeb 2, 202122
NCT02194985Fabry Disease · United States, Argentina, Australia and more3CompletedOct 23, 201984
NCT02082327Fabry Disease · Netherlands1CompletedJun 201431
NCT01853852Fabry Disease · Australia1CompletedDec 201114
NCT01489995Fabry Disease · United States1CompletedDec 201120
NCT01458119Fabry Disease · United States, Argentina, Australia and more3TerminatedFeb 17, 201685
NCT01218659Fabry Disease · United States, Australia, Austria and more3CompletedMay 27, 201468
NCT01196871Fabry Disease · United States, Australia, Belgium and more2CompletedOct 9, 201220
NCT00925301Fabry Disease · United States, Argentina, Australia and more3CompletedJun 12, 201267
NCT00526071Fabry Disease · United States, Australia, Brazil and more2TerminatedSep 8, 201223
NCT00304512Fabry Disease · United States, Australia, Brazil and more2CompletedMay 9, 20089
NCT00283959Fabry Disease · Australia, Brazil2CompletedMay 8, 20084
NCT00283933Fabry Disease · France, United Kingdom2CompletedMar 12, 20085
NCT00214500Fabry Disease · United States2CompletedJan 29, 20089

How it is read

Names in the registry

  • “Lucerastat”, 6 entries
  • “migalastat HCl”, 5 entries
  • “migalastat HCl 150 mg”, 3 entries
  • “migalastat hydrochloride”, 3 entries
  • “Migalastat HCl 20 mg”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.